Watch the dosing and administration video for more information
Please see below for full boxed warning
For detailed instruction on proper vial spiking and product flow, download the product flow guide
For 650-mg or weight-based doses
For small-volume pediatric doses up to 60 mL
OFIRMEV® (acetaminophen) injection is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics, and reduction of fever.
Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that:
OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.
- known hypersensitivity to acetaminophen or to any of the excipients in the intravenous (IV) formulation.
- severe hepatic impairment or severe active liver disease.
To report SUSPECTED ADVERSE REACTIONS, contact Mallinckrodt Pharmaceuticals, at 1.800.778.7898 or FDA at 1.800.FDA.1088 or www.fda.gov/medwatch.
Mallinckrodt, the “M” brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of
a Mallinckrodt company © 2014 Mallinckrodt OFV1421 08/14